Please assess the completion status of the following clinical trial:

Trial Title: Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 18 and 55~* Generally healthy~* Right-handed~* Smoke \>= 5 cigarettes/day of a brand delivering 0.5 mg nicotine (FTC method)~* Have been smoking regularly for \>= 1 year, with a stable smoking pattern over the past 6 months~* Have an expired CO concentration of \>= 10 ppm or urinary cotinine \> 100 ng/ml~* Are able to identify at least 4 smoking and 4 non-smoking enviornments~Exclusion Criteria:~* Inability to attend all required sessions~* Significant health problems that would interfere with completion of study procedures~* Presence of conditions that would make MRI unsafe (e.g. pacemaker)~* Presence of exclusionary psychopathology based on MINI interview (current alcohol/substance use disorder moderate or severe pmild is allowable\], any history of bipolar disorder or psychosis). Individuals in early remission from substance use disorder (not in a controlled environment) may also be allowed at the PIs discretion~* Current use of psychoactive medications per self-report or urine screen. Certain prescribed medications are allowable at the PI's discretion if appropriate documentation (e.g. copy of prescription or physician letter) is provided~* Positive breath alcohol concentraiton Pregnant, breastfeeding, or planning to become pregnant during the course of study~* Problems with vision that cannot be corrected with contacts or glasses~* Current regular use of smokeless tobacco, smoking cessation medications or non-combustible nicotine products (e.g. e-cigarettes)~* Plans to alter smoking pattern (e.g. reduction, uptake, cessation) during course of study~* Current use of beta-adrenergic medication~* Systolic blood pressure \< 90 mmHg or diastolic blood pressure \< 60 mmHg (sitting or standing)~* Low resting heart rate (\< 60 beats per minute)~* Abnormal EKG~* Presence of severe anemia (per complete blood count)~* Presence of electrolyte imbalance that could impact blood pressure (per metabolic panel)~* Presence of any other contraindications for propranolol (e.g. cardiovascular disease, bronchial asthma, prior allergic reaction)~Note that the above criteria reflect general guidelines for decision-making, but ultimate determinations are left to the discretion of the study physician. Presence of minor (e.g. asymptomatic bradycardia in the range of 50-60 in an otherwise healthy adult) or transient (e.g. electrolyte imbalance readily addressed via changes in fluid intake) may still be deemed eligible to participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Propranolol (Type: EXPERIMENTAL): Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete